Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

Patients with relapsed and/or refractory multiple myeloma (RRMM) generally have limited treatment options and a poor prognosis. Previous trials demonstrated that pomalidomide combined with low-dose dexamethasone (Pd) is effective in these patients with significant responses and improved progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wester, Ruth, Dinmohamed, Avinash G., van der Holt, Bronno, Zweegman, Sonja, Minnema, Monique, Croockewit, Sandra, Levin, Mark-David, Libourel, Eduard, de Waal, Esther, Sonneveld, Pieter, Cornelissen, Jan, Blijlevens, Nicole, Broijl, Annemiek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/
https://www.ncbi.nlm.nih.gov/pubmed/35106452
http://dx.doi.org/10.1097/HS9.0000000000000683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797586/
https://www.ncbi.nlm.nih.gov/pubmed/35106452
http://dx.doi.org/10.1097/HS9.0000000000000683

Ejemplares similares